TRULANCE (plecanatide) by Salix Pharmaceuticals is guanylate cyclase activators [moa]. First approved in 2017.
Drug data last refreshed 13h ago · AI intelligence enriched Yesterday
TRULANCE (plecanatide) is an oral small-molecule guanylate cyclase-C agonist approved in 2017 for chronic idiopathic constipation. It works by activating GC-C receptors in the intestine to increase fluid secretion and promote bowel movements. The drug represents a novel mechanism class within the constipation treatment landscape.
Product is in peak lifecycle stage with nearly $120M in annual Part D spending, indicating a stable commercial infrastructure but maturation-phase team dynamics.
Guanylate Cyclase Activators
Guanylate Cyclase-C Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation
Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)
A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
Worked on TRULANCE at Salix Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$119M Medicare spend — this is a commercially significant brand
Working on TRULANCE in 2024 means joining a peak-stage product with established market presence, stable commercial execution, and strong reimbursement (~$119M Part D). Career growth will center on defensive strategies, market share optimization, and preparation for 2034 patent loss rather than launch-phase innovation.